This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Dec;7(12):645.

doi: 10.1038/nrurol.2010.200.

Prostate cancer: Cabazitaxel boosts post-docetaxel survival

PMID: 21188774
DOI: 10.1038/nrurol.2010.200

Comment

Prostate cancer: Cabazitaxel boosts post-docetaxel survival

Lisa Richards. Nat Rev Urol. 2010 Dec.

. 2010 Dec;7(12):645.

doi: 10.1038/nrurol.2010.200.

Author

PMID: 21188774
DOI: 10.1038/nrurol.2010.200

No abstract available

PubMed Disclaimer

Comment on

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. de Bono JS, et al. Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X. Lancet. 2010. PMID: 20888992 Clinical Trial.

References

1. Lancet. 2010 Oct 2;376(9747):1147-54 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.